Patel Pranav M, Essien Utibe R, Happe Laura
Academy of Managed Care Pharmacy/Academy of Managed Care Pharmacy Foundation Joint Research Committee, La Grange, KY.
Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California and Center for the Study of Healthcare Innovation, Implementation, and Policy, VA Greater Los Angeles Healthcare System.
J Manag Care Spec Pharm. 2024 Dec 20:1-11. doi: 10.18553/jmcp.2025.24298.
is a health system and policy goal of ensuring equitable access to high-quality medications for all individuals, regardless of factors such as race, ethnicity, socioeconomic status, or resource availability to reduce health disparities. Although measurement frameworks have been widely used in health equity contexts, a focused framework for pharmacoequity remains a critical gap. In this article, we introduce a novel pharmacoequity measurement framework anchored in the patient medication-use journey. The framework includes the following domains: (1) access to health care services, (2) prescription generation, (3) primary medication nonadherence, (4) secondary medication nonadherence, and (5) medication monitoring. For each domain, we provide examples of outcome measures and potential data sources that can be used for evaluation. We also outline an implementation workflow of the pharmacoequity measurement framework that population health stakeholders can use across various settings (eg, health systems, health plans). The framework provides a structured approach to identify existing gaps in the path toward achieving pharmacoequity and lay the foundation for targeted interventions. Additionally, it enables ongoing monitoring of progress toward achieving pharmacoequity while identifying interventions that are effective, scalable, and sustainable.
是一项卫生系统和政策目标,即确保所有人都能公平获得高质量药物,无论种族、族裔、社会经济地位或资源可得性等因素如何,以减少健康差距。尽管测量框架已在健康公平背景中广泛使用,但针对药物公平性的专门框架仍然存在关键差距。在本文中,我们介绍了一种基于患者用药过程的新型药物公平性测量框架。该框架包括以下领域:(1)获得医疗服务;(2)处方开具;(3)一级药物治疗不依从;(4)二级药物治疗不依从;以及(5)药物监测。对于每个领域,我们提供了可用于评估的结果指标和潜在数据来源的示例。我们还概述了药物公平性测量框架的实施工作流程,人群健康利益相关者可在各种环境(如卫生系统、健康计划)中使用。该框架提供了一种结构化方法,以识别在实现药物公平性道路上的现有差距,并为有针对性的干预措施奠定基础。此外,它能够在识别有效、可扩展和可持续的干预措施的同时,持续监测实现药物公平性的进展情况。